UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.03 Million Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 21.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 33,951 shares of the specialty pharmaceutical company's stock after selling 9,020 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.16% of ANI Pharmaceuticals worth $2,026,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Pacer Advisors Inc. grew its stake in ANI Pharmaceuticals by 23,259.8% in the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company's stock valued at $33,907,000 after buying an additional 565,910 shares during the last quarter. Bank of Montreal Can bought a new stake in ANI Pharmaceuticals during the third quarter valued at about $13,043,000. Millennium Management LLC grew its position in shares of ANI Pharmaceuticals by 1,005.8% in the second quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company's stock valued at $14,651,000 after purchasing an additional 209,272 shares during the last quarter. Mizuho Markets Americas LLC bought a new position in shares of ANI Pharmaceuticals in the third quarter worth about $11,670,000. Finally, Assenagon Asset Management S.A. lifted its position in shares of ANI Pharmaceuticals by 149.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 186,179 shares of the specialty pharmaceutical company's stock worth $11,107,000 after purchasing an additional 111,613 shares during the last quarter. Institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock traded down $0.23 on Monday, hitting $56.36. The company's stock had a trading volume of 315,313 shares, compared to its average volume of 221,858. ANI Pharmaceuticals, Inc. has a one year low of $51.88 and a one year high of $70.81. The firm has a market cap of $1.19 billion, a P/E ratio of -102.89 and a beta of 0.73. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The company has a fifty day moving average price of $58.01 and a 200-day moving average price of $60.29.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating analysts' consensus estimates of $1.09 by $0.25. The business had revenue of $148.30 million for the quarter, compared to analysts' expectations of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm's revenue for the quarter was up 12.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.05 earnings per share. On average, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on ANIP shares. Leerink Partnrs raised ANI Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, December 11th. HC Wainwright restated a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Piper Sandler started coverage on shares of ANI Pharmaceuticals in a research note on Friday, October 11th. They set an "overweight" rating and a $68.00 target price for the company. StockNews.com lowered shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, September 7th. Finally, Truist Financial boosted their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a "hold" rating in a report on Tuesday, October 22nd. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $77.71.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 33,481 shares of the company's stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total value of $1,941,563.19. Following the sale, the chief executive officer now directly owns 370,378 shares in the company, valued at $21,478,220.22. This represents a 8.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total value of $60,000.00. Following the transaction, the senior vice president now directly owns 49,059 shares of the company's stock, valued at approximately $2,943,540. The trade was a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 34,731 shares of company stock valued at $2,015,861. Corporate insiders own 12.70% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.